Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Vadadustat
Therapeutic Area : Nephrology
Study Phase : Approved FDF
Sponsor : MEDICE Health Family
Deal Size : Undisclosed
Deal Type : Agreement
Er-Kim Announces Distribution Agreement with MEDICE for Vafseo® in Europe
Details : Under the agreement, Er-Kim partner with the MEDICE to commercialize the Vafseo (vadadustat). It is being indicated for the treatment of of symptomatic anaemia associated with CKD in adults.
Product Name : Vafseo
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
January 14, 2025
Lead Product(s) : Vadadustat
Therapeutic Area : Nephrology
Highest Development Status : Approved FDF
Sponsor : MEDICE Health Family
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Berotralstat Hydrochloride
Therapeutic Area : Genetic Disease
Study Phase : Approved
Sponsor : BioCryst Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
BioCryst Selects Er-Kim Pharmaceuticals as Commercial Partner for ORLADEYO® (berotralstat) in Turkey
Details : Under the collaboration, Er-Kim Pharmaceuticals will commercialize Orladeyo (berotralstat), the first and only oral therapy designed specifically to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years and older, in Tur...
Product Name : Orladeyo
Product Type : Small molecule
Upfront Cash : Undisclosed
July 19, 2023
Lead Product(s) : Berotralstat Hydrochloride
Therapeutic Area : Genetic Disease
Highest Development Status : Approved
Sponsor : BioCryst Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Approved
Recipient : Nabriva Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the agreement, Er-Kim gains exclusive rights to distribute XENLETA (lefamulin) in the following countries: Bulgaria, Croatia, Czechia, Greece, Hungary, Poland, Romania, Slovakia, and Slovenia.
Product Name : Xenleta
Product Type : Large molecule
Upfront Cash : Undisclosed
July 18, 2022
Lead Product(s) : Lefamulin Acetate
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Approved
Recipient : Nabriva Therapeutics
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : QRX003
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Quoin Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the revenue sharing agreement, which was initially announced earlier in February 2022, ER-Kim gains exclusive rights to commercialize QRX003 in six additional countries. Quoin will be the exclusive supplier of QRX003 to ER-Kim.
Product Name : QRX003
Product Type : Small molecule
Upfront Cash : Undisclosed
March 01, 2022
Lead Product(s) : QRX003
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Quoin Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : QRX003
Therapeutic Area : Rare Diseases and Disorders
Study Phase : Preclinical
Sponsor : Quoin Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the terms of the revenue sharing agreement, ER-Kim gains exclusive rights to commercialize QRX003 in fifteen countries throughout the CEE. Quoin will be the exclusive supplier of QRX003 to ER-Kim.
Product Name : QRX003
Product Type : Small molecule
Upfront Cash : Undisclosed
February 10, 2022
Lead Product(s) : QRX003
Therapeutic Area : Rare Diseases and Disorders
Highest Development Status : Preclinical
Sponsor : Quoin Pharmaceuticals
Deal Size : Undisclosed
Deal Type : Agreement